



OPEN ACCESS

Original research

LGI1 antibody encephalitis: acute treatment comparisons and outcome

Andrew Rodriguez ,¹ C J Klein ,² Elia Sechi ,¹ Eva Alden,³ Michael R Basso,³ Shehroo Pudumjee,³ Sean J Pittock ,² Andrew McKeon ,² Jeffrey W Britton,¹ A Sebastian Lopez-Chiriboga,⁴ Anastasia Zekeridou,² Nicholas L Zalewski,¹ B F Boeve,¹ Gregory S Day ,⁴ Avi Gadoth,⁵ David Burkholder,¹ Michel Toledano,¹ Divyanshu Dubey,² Eoin P Flanagan ²

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2021-327302>).

¹Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

²Department of Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

³Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA

⁴Department of Neurology, Mayo Clinic Hospital Jacksonville, Jacksonville, Florida, USA

⁵Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Correspondence to

Dr Eoin P Flanagan, Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA; flanagan.eoin@mayo.edu

Received 3 June 2021

Accepted 28 October 2021

Published Online First 25 November 2021



► <http://dx.doi.org/10.1136/jnnp-2021-327643>



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Rodriguez A, Klein CJ, Sechi E, et al. *J Neurol Neurosurg Psychiatry* 2022;**93**:309–315.

ABSTRACT

Objective To compare acute treatment responses and long-term outcome in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis.

Methods Retrospective case series of 118 patients with LGI1 antibody encephalitis evaluated at Mayo Clinic across all US sites from 1 May 2008 to 31 March 2019. Patient clinical data were identified and analysed through the neuroimmunology laboratory and electronic medical record. LGI1 antibody detection was by cell-based indirect immunofluorescence assay of serum, cerebrospinal fluid or both. Clinical outcomes were faciobrachial dystonic seizure (FBDS) resolution, modified Rankin Scale (mRS) score, Kokmen Short Test of Mental Status (STMS) score (0–38 point scale) and neuropsychometric testing results.

Results Compared with intravenous immunoglobulin (IVIg) (n=21), patients treated with single-agent acute corticosteroids (intravenous, oral or both) (n=49) were more likely to experience resolution of FBDS (61% vs 7%, p=0.002) and improvements in mRS score (Δ mRS score 2 vs 0, p=0.008) and median Kokmen STMS scores (Δ Kokmen STMS score 5 points vs 0 points, p=0.01). In 54 patients with long-term follow-up (≥ 2 years), the median mRS score was 1 (range 0–6) and the median Kokmen STMS score was 36 (range 24–38) after all combinations of immunotherapy. Neuropsychometric testing in 32 patients with long-term follow-up (≥ 2 years) demonstrated short-term memory impairments in 37%.

Conclusions Corticosteroids appeared more effective acutely than IVIg in improving LGI1 antibody encephalitis in this retrospective comparison of immunotherapies. While improvement with immunotherapy is typical and long-term outcome is favourable, short-term memory deficits are noted in approximately a third of the patients.

INTRODUCTION

Leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis is an autoimmune encephalitis which frequently manifests as an autoimmune limbic encephalitis. Patients may present with subacute onset of memory loss, behavioural disturbances and seizures.¹ Peripheral manifestations, such as neuropathy or autonomic dysfunction, often coexist but may also occur without central involvement.² Faciobrachial dystonic seizure (FBDS) is

highly characteristic of LGI1 antibody encephalitis and is characterised by frequent (up to 40–50 per day), brief (lasting seconds) dystonic movements of the ipsilateral face and arm; it can sometimes involve the leg.³ In addition, autonomic and sensory seizures and paroxysmal dizziness spells without alteration of consciousness have also been described.² A variety of immunotherapies have been shown to be potentially effective (eg, corticosteroids and intravenous immunoglobulins (IVIg)), although no definitive treatment guidelines are available for optimal management, and the choice of the immunosuppressive drug is generally an empirical decision of the treating physician.^{4–16} In late 2019, a small prospective randomised placebo-controlled trial of IVIg in 17 patients with acute symptomatic seizures associated with autoimmune encephalitis (14 with LGI1 autoantibodies) at our facility showed a higher proportion with $\geq 50\%$ seizure reduction in the IVIg arm versus the placebo arm, although many patients went on to subsequently receive corticosteroids due to incomplete response.⁸ While IVIg was more effective than placebo in that study, a direct comparison with corticosteroids was not performed, and comparisons of IVIg to other treatments are generally lacking. In this study, our aims were (1) to compare acute and long-term treatment responses in LGI1 antibody encephalitis with IVIg and corticosteroids and (2) to assess overall long-term functional and cognitive outcomes in patients with LGI1 antibody encephalitis.

METHODS

The Mayo Clinic institutional review board approved this study and all patients consented to the use of their medical records for research purposes.

Patient identification

We retrospectively identified Mayo Clinic patients from 1 May 2008 to 31 March 2019 through the Advanced Cohort Explorer, an electronic retrieval system that interrogates the electronic medical record. Data were cross referenced with our prior studies on LGI1 antibody encephalitis.^{2,17} Inclusion criteria were (1) LGI1 antibody positivity in serum (101 patients), cerebrospinal fluid (5 patients) or both (12 patients); (2) encephalitis; and (3) clinical information available. We excluded patients

without encephalitis (eg, isolated peripheral nervous system disease) or without available clinical details. Ninety-three patients were included in prior studies.^{2,8,17} Of the patients with mouse composite brain tissue results available, immunostaining in a pattern consistent with LGI1 antibodies was identified in 26 of 99 (26%) in serum and 24 of 52 (46%) in cerebrospinal fluid, respectively. Three patients had coexisting contactin-associated protein-like 2 (CASPR2) antibodies.

LGI1-IgG assay

LGI1 and CASPR2 autoantibodies were detected in patient serum or cerebrospinal fluid by transfected cell-based immunofluorescence assay (EUROIMMUN, Lubeck, Germany) and were performed in conjunction with the Mayo Neuroimmunology Laboratory's comprehensive autoantibody evaluation, as described previously.^{18,19}

Clinical evaluation

Two neurologists (AR and EPF) used the Mayo Clinic medical records linkage system to review the medical record for neurological manifestations and examination findings.

Corticosteroid and IVIg treatment regimens

We identified 49 patients who received corticosteroids (intravenous, oral or both) and 21 patients who received IVIg as acute first-line immunotherapy. The corticosteroid and IVIg treatments in this study were not standardised and varied by provider preference, patient choice or inclusion in the prior clinical trial of IVIg in this disease. The treatment regimens could generally be categorised into a few groups. The corticosteroid treatment group typically first underwent an acute course of 1 g of intravenous methylprednisolone once per day for 3–5 days followed by either no additional treatment, by intermittent intravenous steroid infusions (eg, 1 g of intravenous methylprednisolone once per week for 6–12 weeks with subsequent lengthening of the duration between infusions) or by prolonged daily oral prednisone (eg, 1 mg/kg/day with a slow taper over 3–12 months). For IVIg, the typical regimen comprised 0.4 g/kg once per day for 3–5 days alone or followed by intermittent infusions (eg, 0.5 g/kg on day 1 and 1 g/kg (not exceeding 80 g) on day 2 followed by 0.6 g/kg every 2 weeks for two infusions), with the latter used in the previously published clinical trial.⁸

Functional score

Modified Rankin Scale (mRS) was used to assess outcome. The mRS is an ordinal 7-point scoring system that measures neurological disability and has been widely applied to evaluate acute and long-term outcomes in patients with autoimmune encephalitis.²⁰

Cognitive assessments

Long-term cognitive outcome was assessed with the Kokmen Short Test of Mental Status (STMS) and neuropsychometric testing. The Kokmen STMS is a 38-point bedside cognitive scoring system that measures orientation (8 points), attention (7 points), learning (4 points), calculation (4 points), abstraction (3 points), information (4 points), construction (4 points) and recall (4 points).^{21,22}

Neuropsychometric testing assessed global cognitive function (Mattis Dementia Rating Scale); learning memory (Auditory-Verbal Learning Test, delayed recall and California Verbal Learning Test Second Ed. Short Form (CVLT-2-SF)); visual learning and memory (Visual Reproduction Subtest from the Wechsler Memory Scale); language (Boston Naming Test, Controlled Oral Word

Association Test and Category Fluency); visuospatial functioning (Rey-Osterrieth Complex Figure Copy Trial); auditory attention and working memory (Digit Span Subtest from the Wechsler Adult Intelligence Scale); visual attention and processing speed (Trail Making Test Part A); and executive function (Trail Making Test Part B and Stroop Color-Word Test).^{23–36} For the Visual Reproduction and Digit Span tests, Wechsler norms were used.²⁶ For participants who completed the CVLT-2-SF list-learning task, internal CVLT norms were used. All other tests were converted to scaled scores using the Mayo Older Adult Normative Studies (MOANS).^{27,28,30,31} For participants below the MOANS age range (≥ 56 years), the lowest age group was used to determine their scaled score. Participants were then classified into three subgroups based on their scaled score. Scaled scores of ≥ 9 were considered within normal limits. Scaled scores between 6 and 8 were defined as low. Cognitive impairment was defined as a scaled score greater than 1 and a half SD below the mean, which equates to a scaled score of ≤ 5 .

These tests were obtained during the illness course and at the last follow-up.

Other ancillary testing

Brain MRI reports were generated by a radiologist at the last follow-up and were analysed to assess for ongoing signal abnormalities or atrophy with or without prior baseline studies. Seizures were classified based on clinical records and electroencephalogram (EEG) reports, which were generated by a reading epileptologist.

Outcome assessments and definitions

- ▶ Favourable reduction in seizure frequency was defined as a $>50\%$ reduction.
- ▶ Outcomes were considered favourable with an mRS score of 0–2.
- ▶ Relapses were defined as the development of recurrent symptoms at 6 months or longer after an initial clinical improvement.
- ▶ Early recurrence was defined as recurrent symptoms during the first 6 months after an initial improvement with treatment.
- ▶ Clinical improvement in cognition or seizures was determined by the treating physician.
- ▶ Improvements in cognition were objectively analysed in patients who underwent serial cognitive assessments.

Statistical analysis

Continuous and categorical variables were reported as median (range) and number (percentage), respectively. Comparisons across >2 groups were performed with the Kruskal-Wallis test (continuous variables) and the Fisher exact test (categorical variables); pairwise comparisons were performed using the Wilcoxon rank-sum test (continuous variables) and the Fisher exact test (categorical variables). P values of <0.05 were considered statistically significant. We also used regression analyses to assess the potential effects of age, time from onset to treatment and duration from treatment to first follow-up on our inferences about outcomes (mRS score, Kokmen STMS score and FBDS resolution) at first follow-up. For mRS score and Kokmen STMS score, we used linear regression, and for FBDS resolution, we used logistic regression. Analyses were performed with JMP V.14.1 and the R statistical programming language V.4.0.3 software.

RESULTS

One hundred eighteen patients with LGI1 antibody encephalitis were included; the median age at symptom onset was 66 years (range

Table 1 Clinical characteristics and treatments used in 118 patients with LGI1 antibody encephalitis

Characteristics	Value*
Age-at-symptom onset (years), median (range)	66 (17–87)
Male sex	78 (66)
Length of follow-up (months), median (range)	20 (0–184)
Time to treatment (months), median (range)	5 (0–53)
Symptoms at presentation	
Memory loss	103 (87)
Seizures (any type)	104 (88)
Faciobrachial dystonic seizures	62 (53)
Pilomotor seizures	13 (11)
mRS score,† median (range)	3 (0–5)
Accompanying malignancy‡	7 (6)
Kokmen STMS scale score, median (range)	32 (18–38)
Immunosuppressive treatments	
First-line acute treatment	
Intravenous steroids alone (with or without an oral steroid taper)	49 (42)
IVIg only	21 (18)
Intravenous steroids and maintenance immunotherapy	18 (15)
No treatment	12 (10)
Other combination§	18 (15)
Overall treatment at any time point	
Intravenous steroids	93 (79)
IVIg	47 (40)
Oral steroids	41 (35)
Mycophenolate mofetil	38 (32)
Plasma exchange	14 (12)
Azathioprine	12 (10)
Rituximab	11 (9)
Antiseizure medication use	109 (92)

*Represented as n (%) unless otherwise specified.

†Available in 98 patients.

‡Within ±1 year of diagnosis; prostate cancer (four patients), squamous cell carcinoma (two patients), thymoma (one patient) and colorectal cancer (one patient).

§See online supplemental table 1.

IVIg, intravenous immunoglobulin; LGI1, leucine-rich glioma-inactivated 1; mRS, modified Rankin Scale; STMS, Short Test of Mental Status.

17–87), and 78 (66%) patients were male. Patients were treated with one or more immunotherapies over time. Their baseline demographics, clinical characteristics and details on immunotherapies received are summarised in table 1.

Acute immunotherapies

After disease presentation, patients were treated with a single acute immunotherapy (n=70; corticosteroids (intravenous, oral or both) 49, IVIg 21) (online supplemental table 6) and multiple acute immunotherapies (n=36), or received no acute treatment (n=12). The baseline characteristics of patients stratified by type of acute immunotherapy were not significantly different (online supplemental table 7).

Comparison of corticosteroids versus IVIg acute monotherapy

The pretreatment characteristics and disease severity of patients treated with IVIg alone (n=21) and corticosteroids alone (n=49) as acute monotherapy were similar (table 2).

At first follow-up (median 1.4 months, range 0–20 months), patients treated with corticosteroids versus IVIg had more favourable median mRS score (1 vs 3, p=0.004),

Table 2 Subgroup comparison between patients treated acutely with corticosteroids or IVIg monotherapy

	Corticosteroids (n=49)*	IVIg (n=21)	P value
Baseline			
Demographics			
Age at symptom onset (years), median (range)	66 (27–87)	66 (17–79)	0.83
Male sex	37/49 (76%)	14/21 (67%)	0.56
Acute treatment			
Months from onset, median (range)	5 (0–53)	7 (1–15)	0.51
Pretreatment disability			
Memory loss	43/49 (88%)	17/21 (81%)	0.47
mRS score	3 (0–5)	3 (2–4)	0.17
Kokmen STMS scale score, median (range)	33.5 (6–38)	31 (13–37)	0.12
Seizures (any type)	45/49 (92%)	19/21 (91%)	>0.99
FBDS	23/49 (47%)	15/21 (71%)	0.07
Antiseizure medications	46/49 (94%)	19/21 (91%)	0.63
First follow-up			
mRS score	1 (0–5)	3 (0–3)	0.004
Improvement in ΔmRS score	2 (0–4)	0 (0–3)	0.008
Kokmen STMS scale score, median (range)	36 (31–38)	31 (10–37)	0.01
FBDS resolution	14/23 (61%)	1/15 (7%)	0.002
FBDS >50% resolution	18/23 (78%)	4/15 (27%)	0.003
Seizure (any type) resolution	33/44 (75%)#	4/19 (21%)	<0.001
Months after first treatment, median (range)	2 (0–18)	1 (0–20)	0.66
Adverse effects	23/49 (47%)	5/21 (24%)	0.11
Subsequent therapies			
Corticosteroids	22/23 (96%)	13/14 (93%)	>0.99
IVIg	9/23 (39%)	2/14 (14%)	0.15
PLEX	3/23 (13%)	3/14 (21%)	0.65
Maintenance immunotherapy†	14/23 (61%)	6/14 (43%)	0.33
Long-term follow-up after >24 months			
mRS score	1 (0–6)	1 (0–3)	0.45
Improvement in ΔmRS score	.5 (0–3)	1 (0–3)	>0.99
Kokmen STMS scale score, median (range)	37 (28–38)	33.5 (30–36)	0.35
FBDS resolution	8/9 (89%)	4/4 (100%)	>0.99
FBDS >50% resolution	8/9 (89%)	4/4 (100%)	>0.99
Seizure (any type) resolution	20/23 (87%)	7/7 (100%)	>0.99
Patients who relapsed	5/23 (22%)	0/7 (0%)	0.30
Patients with early recurrence	3/23 (13%)	1/7 (14%)	>0.99
Development of hippocampal atrophy/MTS	9/23 (39%)	3/6 (50%)	0.67
Disease duration,‡ median (range)	21 (2–80)	14 (6–68)	0.45

#details not available about seizure resolution in one patient

*33 patients had intravenous steroid monotherapy; 14 patients received intravenous steroids with oral taper; 2 patients received high dose oral steroids with taper but without intravenous steroids.

†Azathioprine, mycophenolate mofetil or rituximab.

‡Months from symptom onset to maximal resolution. FBDS, faciobrachial dystonic seizure; IVIg, intravenous immunoglobulin; mRS, modified Rankin Scale; MTS, mesial temporal sclerosis; PLEX, plasma exchange; STMS, Short Test of Mental Status.

greater overall improvement in mRS score (Δ mRS score 2 vs 0, $p=0.008$), more frequent seizure resolution (33/44 (75%) vs 4/19 (21%), $p<0.001$), more frequent FBDS resolution (14/23 (61%) vs 1/15 (7%), $p=0.002$) and greater improvement in Kokmen STMS score (Δ Kokmen STMS score 5 points vs 0 points, $p=0.01$) (table 2). Of the 19 patients with details available on the speed of FBDS or other seizure resolution, 12 patients treated with corticosteroids and 2 patients treated with IVIg reported complete resolution within the first 7 days from treatment onset. Four patients treated with corticosteroids and one patient treated with IVIg reported symptom resolution within 2 weeks. The age and time from onset to treatment were variable but did not differ between groups (table 2 and online supplemental efigure). A regression analysis showed that when adjusted for time to treatment and time from treatment to first follow-up, corticosteroids when compared with IVIg still led to a reduction in mRS score, improvement in Kokmen STMS score and an increased odds of FBDS resolution (online supplemental table 9 and online supplemental efigure).

Twenty-three (47%) patients in the corticosteroid group and 14 (67%) patients in the IVIg group underwent additional therapies after a median of 1.4 months (range 0.3–13) (table 2). Of the patients in the treatment groups (corticosteroids 23, IVIg 7) with long-term follow-up (≥ 24 months), there were no significant differences in any of our outcomes (table 2). Corticosteroid adverse effects (eg, insomnia, mood disturbance and weight gain) were noted in 23 patients (47%), and IVIg adverse effects (eg, headache, rash, and fatigue) were seen in 5 patients (24%) and were not statistically significantly different ($p=0.11$).

Long-term outcomes

Long-term outcomes were analysed in 54 patients with greater than 24 months of follow-up. Acute immunotherapies in these patients included corticosteroids in 23 patients; other combinations (corticosteroids, IVIg, maintenance immunotherapy or plasma exchange) in 24 patients; and IVIg in 7 patients. Median length of follow-up was 53 months (range 26–184). Favourable mRS score (≤ 2) was seen in 47 of 54 patients (87%), and median mRS score was 1 (range 0–6). The details of mRS at presentation and long-term follow up were available in 49 patients and their distribution at those time-points is shown in figure 1. Median Kokmen STMS score was 36 (range 24–38); patient scores were stable in most other categories, except for delayed recall, where residual difficulties were typical. The median score on delayed recall at the last follow-up was 3 (range 0–4) (online supplemental table 8). Early disease recurrence within 6 months was seen in seven patients (13%). Relapses beyond 6 months were noted in 12 patients (22%), of which 7 were on maintenance immunosuppression and 5 were not. Of these 12 relapses, 9 occurred after complete or near complete remission and 3 occurred in the setting of only partial remission and a fluctuating course. The median time from onset to relapse was 30 months (range 17–138). In the 12 patients who relapsed beyond 6 months, the median number of relapses was 1 (range 1–2). Sixteen patients (30%) had complete response after acute first-line treatment. Thirty-seven (69%) patients were on maintenance immunosuppression at the last follow-up. Three patients (6%) died. Of those patients who died, the median disease duration was 5.3 years (range 3.3–10.4) and the median age at expiration was 72 (range 71–72). Clinical information was available in one patient whom death was from pneumonia and heart failure while in disease remission without concurrent use of acute or maintenance immunotherapy.




Figure 1 Distribution of the modified Rankin Scale in patients with long-term follow-up.

Brain MRI obtained at a median of 29 months (range 2–183) from symptom onset demonstrated hippocampal atrophy or mesial temporal sclerosis in 17 patients (31%) and generalised atrophy in 22 patients (41%). EEG acquired in 45 patients at a median of 39 months after onset (range 4–149) included the following results: normal (24/45 patients, 53%), focal or generalised slowing (15/45 patients, 33%), epileptiform discharges (5/45 patients, 11%) or seizures (1/45 patient, 2%).

Neuropsychometric test results

Neuropsychometric testing was available for 32 patients. One patient was a non-native English speaker, and therefore these data were excluded due to lack of appropriate normative reference group. Data for the remaining 31 patients are presented in table 3.

Due to variability in cognitive tests administered, not all patients completed all measures. Overall, the greatest impairment was found on a screening measure for global cognition and measures of short-term memory/delayed recall and executive function (table 3).

DISCUSSION

This study compares acute immunotherapies and reports the long-term outcome in patients with LGI1 antibody encephalitis. Patients treated with corticosteroids (intravenous, oral or both) compared with IVIg as monotherapy had greater improvements in FBDS, other seizure types, mRS score and Kokmen STMS scores after acute treatment. However, no differences in long-term outcomes were noted between the two groups. Most patients (87%) had favourable mRS score (≤ 2) at follow-up after all combinations of immunotherapy, although residual memory loss, mesial temporal sclerosis and

Table 3 Neuropsychological test data at last available post-treatment assessment*

	N	Scaled score, † median (range)	Within normal limits	Mildly low	Impaired	Per cent impaired (%)
Global screening	15	8 (4–11)	7	2	6	40
Learning and memory						
Verbal list learning	27‡	8 (2–18)	12	10	5	19
List delayed recall	27§	7 (2–17)	10	7	10	37
Visual learning	19	12 (2–17)	13	2	4	21
Visual delayed recall	19	10 (1–16)	14	4	1	5
Language						
Confrontation naming	29	11 (5–16)	25	3	1	3
Lexical fluency	29	10 (5–18)	22	6	1	3
Semantic fluency	28	8.5 (2–19)	14	10	4	14
Visuospatial						
Visuospatial construction	19	10 (2–12)	13	4	2	11
Attention						
Auditory working memory	20	10 (5–18)	16	3	1	5
Visual attention/processing speed	30	9 (2–18)	19	7	4	13
Executive function						
Set shifting	30§	11 (2–18)	20	4	6	20
Cognitive inhibition	18	11.5 (4–17)	12	5	1	6

*Tests used for each domain: Global Screening measure=Dementia Rating Scale 2; Verbal List Learning and List Delayed Recall=AVLT or CVLT-2-SF; Visual Learning and Visual Delayed Recall=Wechsler Memory Scale III/IV, Visual Reproduction Immediate and Delayed Recalls; Confrontation Naming=Boston Naming Test; Lexical Fluency=Controlled Oral Word Association Test; Semantic Fluency=Category Fluency; Visuospatial Construction=Rey-Osterrieth Complex Figure–Copy Condition; Auditory Working Memory=Wechsler Adult Intelligence Scales III/IV, Digit Span; Visual Attention/Processing Speed=Trail Making Test A; Set Shifting=Trail Making Test B; Cognitive Inhibition=Stroop Colour/Word Condition.

†Test scores were transformed to scaled scores; within normal limits=number of patients with scaled scores ≥ 9 , mildly low=number of patients with scaled scores 6–8, impaired=number of patients with scaled scores ≤ 5 .

‡Six patients completed the CVLT-2-SF and 21 completed the AVLT as tests of list learning and memory.

§Three patients did not complete tasks within the required time limit and were considered to have impaired performance on this measure.

AVLT, Auditory–Verbal Learning Test; CVLT-2-SF, California Verbal Learning Test Second Ed. Short Form.

atrophy were noted in a minority. A small proportion of patients had persistent deficits on neuropsychometric testing in global cognition, verbal memory, visual learning and executive function.

The critical importance of early effective immunotherapy in LGI1 antibody encephalitis has been highlighted in prior studies showing that early immunotherapy in FBDS may prevent limbic encephalitis and long-term cognitive deficits, and greater likelihood of a reduction in seizures.⁴ In one study of FBDS, more than half of the patients developed cognitive impairment if FBDS was present for greater than 90 days, with return to baseline function correlated with time to initiation of immunotherapy.⁴ Thus, choosing the most efficacious treatment initially may improve long-term outcomes. While a prior clinical trial showed IVIg is efficacious in LGI1 antibody encephalitis, the effect size was small. Comparisons such as this may inform treatment approaches that may be more effective. Our findings, although retrospective, suggest that corticosteroids (typically intravenous at high dose) may be more efficacious than IVIg as acute treatment in LGI1 antibody encephalitis. These results have potential clinical implications. First, it suggests that corticosteroids should be considered as first-line treatment in LGI1 antibody encephalitis. Second, it suggests that early rescue with corticosteroid treatment should be considered in patients without complete response to IVIg by 7 days, the timeline by which 90% of patients in this study had cessation of FBDS. Third, it suggests that a corticosteroid treatment arm should be included in future randomised controlled trials in this disease.

Our findings are consistent with prior cohort studies of LGI1 antibody encephalitis in which corticosteroids were used in at least 90% of patients with most showing improvement. By contrast, IVIg was typically used in less than one-third of patients and rarely used in isolation.^{3–5,9} FBDS cessation in prior studies that used corticosteroids as the mainstay was 51% within 30 days

compared with 61% at first follow-up in our study. This compares to two of eight patients (25%) achieving seizure freedom after 5 weeks in the IVIg arm of the prior randomised controlled clinical trial that included patients with all seizure types rather than FBDS alone.⁸ It is also notable that 9 of 12 patients (75%) in that study went on to receive corticosteroid treatment, with seizure resolution observed in the majority.⁸ In the study by Irani *et al*, IVIg was considered ineffective in four of six patients (67%), who received it acutely as monotherapy; those patients subsequently received corticosteroids.³ In other studies by Thompson *et al* (103 patients), van Sonderen *et al* (32 patients) and de Bruijn *et al* (46 patients); only a minority (two patients or less) in each study received IVIg as acute monotherapy precluding definitive comparisons from those studies.^{4,5,9} The majority of patients in this study received 1 g of intravenous methylprednisolone once per day for 3–5 days often followed by either intermittent high-dose intravenous steroids or high-dose oral steroids (1 mg/kg) followed by a slow taper over 6–12 months. The relative efficacy of high-dose oral versus intermittent intravenous steroids could not be well ascertained from this study; although prolonged high dose oral steroids with slow taper was previously noted to be beneficial in refractory cases and is the first-line approach, we currently favour with or without maintenance immunosuppression.¹⁷ The exact reasons for greater efficacy with steroids than IVIg is not clear, but we hypothesise it may relate to its IgG subclass. LGI1 antibodies are predominantly of IgG4 subclass, and these diseases (eg, IgG4 related disease) tend to respond well to the broad immunosuppressive effects of steroids.^{37,38} Moreover, IVIg has some modulatory effects on the complement pathway that are protective and may explain its benefit with IgG1-mediated autoimmune neurological disorders

that activate complement but lower efficacy with IgG4-mediated diseases that cannot activate complement.³⁹

Most patients in this study had favourable functional outcomes after long-term follow-up and multiple immunotherapies. However, a substantial minority had persistent dysfunction in verbal memory and visual learning. These findings are consistent with prior studies in patients with LGI1 antibody encephalitis.^{2 5 40–44} According to Finke *et al*, verbal and visuospatial memory deficits were persistent after disease remission.⁴⁰ A telemedicine study by Sola-Valls *et al* demonstrated impairment in verbal fluency (53%), verbal memory (50%) and executive function impairment (31%) at long-term follow-up, which is slightly higher compared with our findings.⁴² Findings from Binks *et al* similarly showed 81% having a good outcome of mRS score of ≤ 2 , with memory, fluency and visuospatial impairments with prominent fatigue.⁴⁴ Notably, only four of 27 (15%) were able to return to their prior job positions despite the overall good mRS score highlighting a limitation in that outcome measure.⁴⁴ These are further supported in this study by MRI evidence of hippocampal atrophy, mesial temporal sclerosis and generalised atrophy, all of which are integral to learning, memory and executive function. Hippocampal volume loss and generalised atrophy were common findings in prior studies and are suggestive of long-term or permanent hippocampal and global cerebral dysfunctions after disease remission.^{5 40 41 43 45}

One of the limitations associated with this study is its retrospective nature. Despite this and the lack of randomisation, patients' characteristics in both treatment arms were balanced, increasing confidence in the results. While retrospective data cannot replace prospective randomised placebo-controlled data, it is unclear whether prospective studies of corticosteroids will be undertaken in LGI1 antibody encephalitis, given its low-cost, generic formulation, importance of expediency of treatment referable to outcome and relative rarity of the disease, making it less attractive for pharmaceutical companies to fund. Thus, analyses such as this are important to provide some guidance for treatment selection. Additional limitations include lack of standardised cognitive assessments, but this provides a large detailed analysis of cognitive outcomes in LGI1 antibody encephalitis that are useful for prognostication. Finally, we compared steroids and IVIg treatments at first follow-up, and small numbers and variable follow-up times limited our ability to compare the steroid and IVIg outcomes at set time points. However, when controlling for time from onset to treatment and time from treatment to first follow-up, the overall findings did not change.

In summary, this retrospective study suggests that acute treatment with corticosteroids may be more effective than IVIg in improving acute outcomes in patients with LGI1 antibody encephalitis. While most patients improved with immunotherapy, residual long-term memory deficits were common. These observations highlight the need to incorporate a corticosteroid treatment arm into future randomised controlled trials enrolling patients with LGI1 antibody encephalitis. The presence of residual deficits despite early treatment in the majority of this cohort indicates the clinical need for identification of other treatment options in these patients in order to optimise recovery.

Twitter Elia Sechi @EliaSechi, A Sebastian Lopez-Chiriboga @mdsebaslopez, Gregory S Day @GDay_Neuro and Eoin P Flanagan @EoinFlanagan14

Contributors AR and EPF conceived the study and were responsible for the overall content of the study. AR, EPF, CJK and AG performed data collection. Mayo Clinic Division of Biomedical Statistics, ES and AR performed the statistical analysis. EA, MRB and SP obtained neuropsychometric testing and performed the statistical analysis. AR, ES, EA, MRB, SP and EPF designed the tables. AR and EPF drafted the manuscript. EPF, CJK, MRB, SP, AM, JWB, ASL-C, AZ, NLZ, BFB, GSD, AG, DB, MT and DD provided senior review of the manuscript. EPF is responsible for the overall content and guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The Mayo Clinic Institutional Review Board approved this study (ID: 08-006647) and all patients consented to the use of their medical records for research purposes.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Andrew Rodriguez <http://orcid.org/0000-0002-6716-6684>

C J Klein <http://orcid.org/0000-0002-4012-8856>

Elia Sechi <http://orcid.org/0000-0003-4698-663X>

Sean J Pittock <http://orcid.org/0000-0002-6140-5584>

Andrew McKeon <http://orcid.org/0000-0001-6856-8143>

Gregory S Day <http://orcid.org/0000-0001-5133-5538>

Eoin P Flanagan <http://orcid.org/0000-0002-6661-2910>

REFERENCES

- Lai M, Huijbers MGM, Lancaster E, *et al*. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. *Lancet Neurol* 2010;9:776–85.
- Gadoth A, Pittock SJ, Dubey D, *et al*. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. *Ann Neurol* 2017;82:79–92.
- Irani SR, Michell AW, Lang B, *et al*. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. *Ann Neurol* 2011;69:892–900.
- Thompson J, Bi M, Murchison AG, *et al*. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. *Brain* 2018;141:348–56.
- van Sonderen A, Thijs RD, Coenders EC, *et al*. Anti-Lgi1 encephalitis: clinical syndrome and long-term follow-up. *Neurology* 2016;87:1449–56.
- Irani SR, Gelfand JM, Bettcher BM, *et al*. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. *JAMA Neurol* 2014;71:896–900.
- Irani SR, Stagg CJ, Schott JM, *et al*. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. *Brain* 2013;136:3151–62.
- Dubey D, Britton J, McKeon A, *et al*. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. *Ann Neurol* 2020;87:313–23.
- de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, *et al*. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABAb>Bb>R encephalitis. *Neurology* 2019;92:e2185–96.
- Steriade C, Moosa ANV, Hantus S, *et al*. Electroclinical features of seizures associated with autoimmune encephalitis. *Seizure* 2018;60:198–204.
- Dubey D, Singh J, Britton JW, *et al*. Predictive models in the diagnosis and treatment of autoimmune epilepsy. *Epilepsia* 2017;58:1181–9.
- Toledano M, Britton JW, McKeon A, *et al*. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. *Neurology* 2014;82:1578–86.
- Gao L, Liu A, Zhan S, *et al*. Clinical characterization of autoimmune LGI1 antibody limbic encephalitis. *Epilepsy Behav* 2016;56:165–9.
- Shin Y-W, Lee S-T, Shin J-W, *et al*. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. *J Neuroimmunol* 2013;265:75–81.
- Irani SR, Alexander S, Waters P, *et al*. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, morvan's syndrome and acquired neuromyotonia. *Brain* 2010;133:2734–48.

- 16 Quek AML, Britton JW, McKeon A, *et al.* Autoimmune epilepsy: clinical characteristics and response to immunotherapy. *Arch Neurol* 2012;69:582–93.
- 17 Flanagan EP, Kotsenas AL, Britton JW, *et al.* Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e161.
- 18 Klein CJ, Lennon VA, Aston PA, *et al.* Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. *JAMA Neurol* 2013;70:229–34.
- 19 Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. *Ann Neurol* 2004;56:715–9.
- 20 van Swieten JC, Koudstaal PJ, Visser MC, *et al.* Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19:604–7.
- 21 Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. *Mayo Clin Proc* 1987;62:281–8.
- 22 Townley RA, Syrjanen JA, Botha H, *et al.* Comparison of the short test of mental status and the montreal cognitive assessment across the cognitive spectrum. *Mayo Clin Proc* 2019;94:1516–23.
- 23 Benton AL BA, Sivan AB, *et al.* *Contributions to neuropsychological assessment: a clinical manual.* Oxford University Press, 1994.
- 24 Benton AL, Kd H. *Multilingual aphasia examination : manual of instructions.* Iowa City: Dept. of Neurology and Psychology, University of Iowa, 1983.
- 25 Chlebowska C. Wechsler memory scale all versions. In: *Encyclopedia of clinical neuropsychology*, 2001.
- 26 Drozdick LW, Wahlstrom D, Zhu J. The wechsler adult intelligence scale—fourth edition and the wechsler memory scale—fourth edition.. In: *Contemporary intellectual assessment: theories, tests, and issues.* 3rd edn. New York, NY, US: The Guilford Press, 2012: 197–223.
- 27 Ivnik RJ, Malec JF, Smith GE, *et al.* Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO. *Clin Neuropsychol* 1996;10:262–78.
- 28 Ivnik RJ, Malec JF, Smith GE, *et al.* Mayo's older americans normative studies: updated AVLT norms for ages 56 to 97. *Clin Neuropsychol* 1992;6:83–104.
- 29 Kaplan E, Goodglass H, Weintraub S. *Boston naming test.* Philadelphia: Lea & Febiger, 1983.
- 30 Lucas JA, Ivnik RJ, Smith GE, *et al.* Mayo's older Americans normative studies: category fluency norms. *J Clin Exp Neuropsychol* 1998;20:194–200.
- 31 Lucas JA, Ivnik RJ, Smith GE, *et al.* Normative data for the mattis dementia rating scale. *J Clin Exp Neuropsychol* 1998;20:536–47.
- 32 Mattis S. Dementia rating scale: professional manual. In: *Psychological assessment resources*, 1988.
- 33 Reitan RMaW D. *The halstead-reitan neuropsychological test battery: theory and clinical interpretation.* Neuropsychology Press, 1993.
- 34 Rey A. *L'examen clinique en psychologie.* Paris: Presses universitaires de France, 1964.
- 35 Ryan JJ, Lopez SJ. Wechsler adult intelligence scale-III. In: *Understanding psychological assessment perspectives on individual differences*, 2001.
- 36 Yi A. California verbal learning test (california verbal learning test-II). In: Kreutzer JS, DeLuca J, Caplan B, eds. *Encyclopedia of clinical neuropsychology.* New York, NY: Springer New York, 2011: 475–6.
- 37 Gadoth A, Zekeridou A, Klein CJ, *et al.* Elevated LGI1-IgG CSF index predicts worse neurological outcome. *Ann Clin Transl Neurol* 2018;5:646–50.
- 38 Khosroshahi A, Wallace ZS, Crowe JL, *et al.* International consensus guidance statement on the management and treatment of IgG4-related disease. *Arthritis Rheumatol* 2015;67:1688–99.
- 39 Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. *Int Immunol* 2017;29:491–8.
- 40 Finke C, Prüss H, Heine J, *et al.* Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, Glioma-Inactivated 1 antibodies. *JAMA Neurol* 2017;74:50–9.
- 41 Malter MP, Frisch C, Schoene-Bake JC, *et al.* Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. *J Neurol* 2014;261:1695–705.
- 42 Sola-Valls N, Ariño H, Escudero D, *et al.* Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2020;7. doi:10.1212/NXI.0000000000000652. [Epub ahead of print: 17 12 2019].
- 43 Szots M, Blaabjerg M, Orsi G, *et al.* Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: a prospective multimodal MRI study. *J Neurol Sci* 2017;376:159–65.
- 44 Binks SNM, Veldsman M, Easton A, *et al.* Residual fatigue and cognitive deficits in patients after leucine-rich Glioma-Inactivated 1 antibody encephalitis. *JAMA Neurol* 2021;78:617.
- 45 Loane C, Argyropoulos GPD, Roca-Fernández A, *et al.* Hippocampal network abnormalities explain amnesia after VGKCC-Ab related autoimmune limbic encephalitis. *J Neurol Neurosurg Psychiatry* 2019;90:965–74.

eTable 1. Patients with Other First-Line Acute Treatment Combinations

Treatment	No. (%)
IV steroids and IVIg	5 (4)
IV steroids, IVIg, and maintenance immunotherapy	3 (3)
IV steroids, plasma exchange, and maintenance immunotherapy	2 (2)
IVIg and plasma exchange	2 (2)
IV steroids and plasma exchange	1 (1)
IV steroids, oral steroids, and maintenance immunotherapy	1 (1)
IV steroids, IVIg, and oral steroids	1 (1)
IVIg and maintenance immunotherapy	1 (1)
IVIg, plasma exchange, and oral steroids	1 (1)
Oral steroids and maintenance immunotherapy	1 (1)

Abbreviation: IVIg, intravenous immunoglobulins.

eTable 2. Corticosteroid and IVIg Acute Treatment Regimens

Corticosteroid Treatment Regimen	Number of Patients (n=49)
IVMP 1g QD x 5 d	9
IVMP 1g QD x 3 d; IVMP 1g QW x 6 w; IVMP 1g QoW x 6 w	3
IVMP 1g QD x 5 d; pred 40mg QD x 1 m; pred x 30mg QD x 1 m; pred 20mg QD x 1 m; pred 15mg QD x 1 m; pred 10mg QD x 1 m; pred 9mg QD x 2 w; pred 8mg QD x 2 w; pred 7mg QD x 2 w; pred 6mg QD x 2 w; pred 5mg QD x 2 w; pred 4mg QD x 2 w; pred 3mg QD x 2 w; pred 2mg QD x 2 w; pred 1mg QD x 2 w	3
IVMP 1g QD x 3 d; IVMP 1g QW x 12 w	2
IVMP 1g QD x 5 d; IVMP 1g QW x 6 w	2
IVMP 1g QD x 5 d; IVMP 1g QW x 6 w; IVMP 1g QoW x 6 w	2
IVMP 1g QD x 2 d	1
IVMP 1g QD x 3 d	1
IVMP 1g QD x 3 d; IVMP 1g QW x 6 w; IVMP 1g QoW x unknown w; IVMP 1g QM x unknown m	1
IVMP 1g QD x 5 d; pred 80mg taper x unknown days	1
IVMP 1g QD x 5 d; IVMP 1g BIW x 3 m	1
IVMP 1g QD x 5 d; IVMP 1g QM	1
IVMP 1g QD x 5 d; IVMP 1g QW x 11 w; IVMP 500mg QoW x 8 w; IVMP 500mg every 3 w x 9 w; IVMP 500mg every 4 w x 12 w	1
IVMP 1g QD x 5 d; IVMP 1g QW x 3 w; IVMP 1g QoW x 5 m	1
IVMP 1g QD x 5 d; IVMP 1g QW x 5 w; pred 80mg QD x 3 m; pred taper 10mg m x 7 m; pred 1mg taper x 10 m	1
IVMP 1g QD x 5 d; IVMP 1g QW x 6 w; IV taper over 6 m	1
IVMP 1g QD x 5 d; IVMP 1g QW x 6 w; IVMP 1g QoW x 8 w	1
IVMP 1g QD x 5 d; pred 40mg QD taper x 6 w	1
IVMP 1g QD x 5 d; pred 60mg QD x 2 w; pred 40mg QD x 12 w; slow taper	1
IVMP 1g QD x 5 d; pred 60mg QD x 3 m taper	1
IVMP 1g QD x 5 d; pred 60mg QD x 3 m; pred taper 10mg per m x 5 m; pred 1mg taper x 10 m	1
IVMP 1g QD x 5 d; pred 60mg taper x 3 m	1
IVMP 1g QD x 5 d; pred 60mg taper x 7 d	1
IVMP 1g QW x 12 w; IVMP 750mg QW x 6 m; slow taper	1
IVMP 1g QW x 6 w	1
IVMP 1g QW x 6 w; IVMP 1g QW QoW x 6 w	1
IVMP 500mg QD x 5 d; pred taper over 2 m	1
pred 200mg QD x 5 d	1
IVMP 60mg every 6 hours x 7 d	1
pred 80mg QD x 2 w; pred 60mg QD x 1 week; pred 40mg QD x 1 week; pred 20mg QD x 1 week; pred 10mg QD x 1 w; pred 5mg QD x 1 week	1
"Intermittent IVMP x 6 m followed by taper over 6 m"	1
"IV steroids followed by prolonged taper starting at pred 35mg"	1
"Therapeutic trial of steroids"	1
"Trial of steroids"	1
IVIg Treatment Regimen	Number of Patients (n=21)
Week 1: IVIg 0.5g/kg QD x 1 d, IVIg 1g/kg QD x 1 d; Week 3: IVIg 0.6g/kg QD x 1 d; Week 5: IVIg 0.6g/kg QD x 1 d	13
IVIg 0.4g/kg QD x 5 d	3
IVIg 0.4g/kg QD x 3 d; IVIg 0.4g/kg QW x 12 w	1
IVIg 0.4g/kg QD x 5 d; IVIg 0.4g/kg every 4 w	1
IVIg 0.4g/kg QD x 5 d; IVIg 0.4g/kg QoW x 8 w	1
IVIg 0.4g/kg QD x 3 d; IVIg 0.4g/kg QW x 6 w	1
"IVIg on a weekly basis" x 3 m	1

Abbreviations: BIW, twice every week; d, days; g, grams; IVIg, intravenous immunoglobulins; IVMP, intravenous methylprednisolone; m, months; mg, milligrams; pred, prednisone; QD, once daily; QM, once monthly; QoW, once every other week; QW, once weekly; w, weeks; x, times.

eTable 3. Baseline Characteristics of Patients with LGI1 Antibody Encephalitis Stratified by Type of Acute Immunotherapy

	Patients (n = 118)	Untreated (n = 12)	Multiple IT (n = 36)	Monotherapy (n = 70)	P Value
Demographics					
Age-at-symptom onset, median (range)	66 (17-87)	61 (47-79)	65 (36-80)	66 (17-87)	.73
Male sex	78/118 (66%)	7/12 (58%)	20/36 (56%)	51/70 (73%)	.17
Clinical characteristics at presentation					
Memory loss	103/118 (87%)	10/12 (83%)	33/36 (92%)	60/70 (86%)	.65
mRS, median (range)	3 (0-5)	3 (1-3)	3 (2-5)	3 (0-5)	.29
Kokmen STMS scale score, median (range)	32 (18-38)	37 (22-38)	30.5 (18-38)	33 (24-38)	.32
Seizures (any type)	104/118 (88%)	8/12 (67%)	32/36 (89%)	64/70 (91%)	.05
Faciobrachial dystonic seizures	62/118 (53%)	3/12 (25%)	21/36 (58%)	38/70 (54%)	.14
Pilomotor	13/118 (11%)	0/12 (0%)	5/36 (14%)	8/70 (11%)	.56

Abbreviations: IT, immunotherapy; mRS, modified Rankin Scale; STMS, Short Test of Mental Status.

eTable 4. Median Kokmen STMS Scores in Patients with Long-Term Follow-up

	At Presentation (n = 28)	At Last Follow-up (n = 28)
Orientation	8	8
Attention	7	7
Learning	4	4
Calculation	4	4
Abstraction	3	3
Construction	4	4
Information	4	4
Recall	2	3
Total	34	36


Abbreviation: STMS, Short Test of Mental Status.

Maximum scores for each category: Orientation (8 points), Attention (7 points), Learning (4 points), Calculation (4 points), Abstraction (3 points), Construction (4 points), Information (4 points), Recall (4 points), Total (38 points).

Outcome	Adjusted for time from onset to treatment		Adjusted for time from onset to treatment and time from treatment to first follow-up	
	Estimate (95% CI)*	P-value	Estimate (95% CI)*	P-value
mRS				
Full sample	-0.9 (-1.5, -0.3)	0.006	-0.8 (-1.5, -0.2)	0.01
Subset	-0.8 (-1.5, -0.1)	0.02	-0.8 (-1.6, -0.1)	0.03
Kokmen STMS				
Full sample	6.3 (2.4, 10.3)	0.003	5.9 (0.9, 10.9)	0.02
Subset	6.3 (1.8, 10.8)	0.008	4.8 (-1.3, 10.8)	0.11
Odds of FBDS resolution				
Full sample	12 (4, 52)	<0.001	14 (3, 87)	0.001
Subset	10 (3, 43)	<0.001	11 (2, 67)	0.004

eTable. Regression analyses adjusted for time from onset to treatment and time from treatment to 1st follow-up. Effect sizes from regression models of outcomes at first follow-up comparing those treated with corticosteroids versus those treated with IVIg. Estimates are shown for the full sample and the highly comparable subset with age of onset 55–80 and time from onset to treatment of ≤ 20 months.

* Estimates and 95% CIs for mRS and Kokmen STMS are the group difference in mean scores. Estimates for FBDS resolution and FBDS >50% resolution are the relative odds of the favorable outcome for the corticosteroids group versus the IVIg group.

eFigure. Time from Onset to Treatment Versus Age of Onset

Abbreviation: IVIg, intravenous immunoglobulins.

The two groups did not differ systematically in terms of either age of onset ($p=0.83$) or time from onset to treatment ($p=0.51$). The gray region covers onset ages from 55–80 and treatments undertaken within 20 months and represents a subset of 36 individuals treated with corticosteroids and 20 individuals treated with IVIg who are highly comparable in terms of these baseline factors.